NO20010047L - Antivirale makrocykliske forbindelser - Google Patents

Antivirale makrocykliske forbindelser

Info

Publication number
NO20010047L
NO20010047L NO20010047A NO20010047A NO20010047L NO 20010047 L NO20010047 L NO 20010047L NO 20010047 A NO20010047 A NO 20010047A NO 20010047 A NO20010047 A NO 20010047A NO 20010047 L NO20010047 L NO 20010047L
Authority
NO
Norway
Prior art keywords
antiviral
macrocyclic compounds
macrocyclic
compounds
antiviral macrocyclic
Prior art date
Application number
NO20010047A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010047D0 (no
Inventor
Gary James Bridger
Eva Maria Boehringer
Zhongren Wang
Dominique Schols
Renato Tony Skerlj
David Earl Bogucki
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20010047D0 publication Critical patent/NO20010047D0/no
Publication of NO20010047L publication Critical patent/NO20010047L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Structural Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20010047A 1998-07-08 2001-01-04 Antivirale makrocykliske forbindelser NO20010047L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/111,895 US6506770B1 (en) 1996-06-06 1998-07-08 Antiviral compounds
PCT/CA1999/000619 WO2000002870A1 (fr) 1998-07-08 1999-07-08 Composes antiviraux macrocycliques

Publications (2)

Publication Number Publication Date
NO20010047D0 NO20010047D0 (no) 2001-01-04
NO20010047L true NO20010047L (no) 2001-03-01

Family

ID=22341015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010047A NO20010047L (no) 1998-07-08 2001-01-04 Antivirale makrocykliske forbindelser

Country Status (17)

Country Link
US (6) US6506770B1 (fr)
EP (1) EP1095031B1 (fr)
JP (1) JP4637353B2 (fr)
KR (1) KR100778134B1 (fr)
CN (2) CN1195745C (fr)
AP (1) AP1436A (fr)
AU (1) AU767359B2 (fr)
BR (1) BR9912524A (fr)
CA (1) CA2336634C (fr)
HU (1) HUP0102930A3 (fr)
IL (1) IL140605A0 (fr)
MX (1) MXPA01000137A (fr)
NO (1) NO20010047L (fr)
NZ (1) NZ509699A (fr)
PL (1) PL345516A1 (fr)
TR (1) TR200100030T2 (fr)
WO (1) WO2000002870A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
CA2389545C (fr) 1999-12-17 2010-08-31 Anormed Inc. Recepteur de chemokine liant des composes heterocycliques
BR0113931A (pt) * 2000-09-15 2004-01-13 Anormed Inc Compostos heterocìclicos ligantes receptores de quimiocinas
US7052676B2 (en) * 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
NZ530169A (en) * 2001-07-31 2007-04-27 Anormed Inc Methods to mobilize progenitor/stem cells
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en) * 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
ATE453386T1 (de) 2003-04-02 2010-01-15 Taigen Biotechnology Co Ltd Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
EP1613613B1 (fr) 2003-04-11 2021-06-02 Genzyme Corporation Composes de liaison aux recepteurs de chimiokine cxcr4
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
WO2005051927A1 (fr) * 2003-11-26 2005-06-09 Kureha Corporation Procede de culture de lymphocytes t cd4 positifs par l'intermediaire d'une culture de vih-1, et inhibiteur de croissance du vih-1
BRPI0514343A (pt) * 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006116185A2 (fr) * 2005-04-25 2006-11-02 Cbr Institute For Biomedical Research, Inc. Procedes destines au traitement de myelomes multiples
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
WO2007036036A1 (fr) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Methode et composition pour moduler une greffage de cellules souches
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
EP2043640A2 (fr) * 2006-06-12 2009-04-08 Pfizer Products Inc. Antagonistes de ccr5 pour l' amelioration de la reconstitution immunitaire et le traitement d' une infection opportuniste chez des patients atteints du vih
MX2009001272A (es) * 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
AR062271A1 (es) * 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
US20090274687A1 (en) * 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders
WO2010088401A1 (fr) * 2009-01-30 2010-08-05 Genzyme Corporation Procédés et compositions de traitement d'un cancer du sein
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド E−セレクチンおよびcxcr4ケモカイン受容体のヘテロ二官能性阻害剤
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012061662A1 (fr) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Inhibiteurs glycomimétiques-peptidomimétiques de sélectines e et de récepteurs de chimiokine cxcr4
PL2709991T3 (pl) 2011-05-16 2021-04-06 Genzyme Corporation Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
AU2012358150B2 (en) 2011-12-22 2017-07-20 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
CN104837492B (zh) 2012-12-07 2018-04-27 糖模拟物有限公司 使用e-选择素拮抗剂动员造血细胞的化合物、组合物和方法
CN103058998B (zh) * 2013-01-16 2016-04-13 山东鲁北药业有限公司 一种amd3465的制备工艺
EP3227310B1 (fr) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Inhibiteurs hétérobifonctionnels des e-sélectines et des récepteurs aux chimiokines cxcr4
EP3277284B1 (fr) * 2015-04-02 2020-08-05 Proximagen, Llc Nouvelles thérapies de cancer
US10709697B2 (en) 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
EP3364965A4 (fr) * 2015-10-19 2019-06-26 Ramot at Tel-Aviv University Ltd. Méthodes et compositions pour le traitement de maladies neurodégénératives
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
DK3393468T3 (da) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Fremgangsmåder til behandling af en immundefektsygdom
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017216373A1 (fr) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス, インコーポレイテッド E−セレクチンの阻害剤もしくはcxcr4の阻害剤との、またはe−セレクチンおよびcxcr4両方のヘテロ二機能性阻害剤とのt細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (fr) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Dérivés de galactopyranosyle-cyclohexyle utilisés en tant qu'antagonistes d'e-sélectine
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (fr) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions et procédés de multiplication de cellules souches et progénitrices hématopoïétiques
EP3717013A1 (fr) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
IL275077B1 (en) 2017-12-06 2024-10-01 Magenta Therapeutics Inc Dosing regimens for the mobilization of stem cells and hematopoietic progenitor cells.
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
EP3732186A1 (fr) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Inhibiteurs hétérobifonctionnels de e-sélectine et de galectine -3
US20200338132A1 (en) 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
EP3761994A1 (fr) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Méthodes de traitement de la leucémie aiguë myéloïde et d'états pathologiques associés
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020139962A1 (fr) 2018-12-27 2020-07-02 Glycomimetics, Inc. Inhibiteurs hétérobifonctionnels d'e-sélectine et de galectine-3
EP4051298A1 (fr) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (fr) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
WO2000009152A1 (fr) 1998-08-14 2000-02-24 The University Of British Columbia Antagonistes therapeutiques du recepteur de la chimiokine
EP2311495B1 (fr) 1998-03-24 2014-09-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la vascularisation
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
WO2005002522A2 (fr) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions et methodes pour traiter une ischemie tissulaire
US7315917B2 (en) * 2005-01-20 2008-01-01 Sandisk Corporation Scheduling of housekeeping operations in flash memory systems

Also Published As

Publication number Publication date
CN1308617A (zh) 2001-08-15
US6872714B1 (en) 2005-03-29
KR20010071764A (ko) 2001-07-31
NO20010047D0 (no) 2001-01-04
CN1195745C (zh) 2005-04-06
AP2001002043A0 (en) 2001-03-31
TR200100030T2 (tr) 2001-06-21
US20080287454A1 (en) 2008-11-20
US20040235814A1 (en) 2004-11-25
PL345516A1 (en) 2001-12-17
HUP0102930A2 (hu) 2001-11-28
JP4637353B2 (ja) 2011-02-23
MXPA01000137A (es) 2002-11-29
EP1095031A1 (fr) 2001-05-02
US6506770B1 (en) 2003-01-14
US20050154005A1 (en) 2005-07-14
US6756391B2 (en) 2004-06-29
EP1095031B1 (fr) 2013-08-21
IL140605A0 (en) 2002-02-10
NZ509699A (en) 2003-10-31
CA2336634A1 (fr) 2000-01-20
AP1436A (en) 2005-06-22
US20030018189A1 (en) 2003-01-23
US7160872B2 (en) 2007-01-09
CA2336634C (fr) 2009-05-19
AU767359B2 (en) 2003-11-06
JP2002520323A (ja) 2002-07-09
KR100778134B1 (ko) 2007-11-27
US7414065B2 (en) 2008-08-19
US7709486B2 (en) 2010-05-04
CN1679562A (zh) 2005-10-12
CN100339080C (zh) 2007-09-26
WO2000002870A1 (fr) 2000-01-20
AU4595999A (en) 2000-02-01
HUP0102930A3 (en) 2002-06-28
BR9912524A (pt) 2001-05-02

Similar Documents

Publication Publication Date Title
NO20010047D0 (no) Antivirale makrocykliske forbindelser
BR9709643A (pt) Compostos antivirais
LTPA2009006I1 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
EE200100600A (et) FAP-aktiveeritud kasvajavastased ühendid
PT930302E (pt) Derivados de benzo-sulfona
NO20011745L (no) Forbindelser
NO20006520D0 (no) Adenosinderivater
PT1104422E (pt) Derivados de fenilxantina
NO20005795D0 (no) Antivirale forbindelser
ID27004A (id) Senyawa-senyawa kalsilitik
PT928790E (pt) Derivados de tiazolo
NO20006662L (no) Fluorfenylresin-forbindelser
PT1056716E (pt) Derivados de ciclo-hexanodiolo
BR9709432A (pt) Composto antivirais
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE233253T1 (de) Chromanderivate
NO20011358L (no) Antivirale kombinasjoner
BR9709528A (pt) Compostos antivirais
DK1054867T3 (da) Antivirale midler
DK1060183T3 (da) 5-deoxycytidinderivater
PT1123283E (pt) Derivados de tiazole
PT928793E (pt) Derivados de tiazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application